Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyUnivera Thermal Ablation Coverage Update | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedUnivera HealthcarePolicy 7.01.111

    Thermal Ablation for Solid Tumor Treatment

    Customize your policy alerts

    Sign up for univerahealthcare Policy 7.01.111 alerts

    Get alerted when Policy 7.01.111 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when radiofrequency ablation, cryoablation, and microwave ablation are medically appropriate for selected primary and metastatic solid tumors, including tumors of the liver, kidney, lung, bone, and osteoid osteoma.

    Policy Summary
    PayerUnivera Healthcare
    PolicyThermal Ablation for Solid Tumor Treatment
    Policy CodePolicy 7.01.111
    Change TypeModified
    Effective DateNovember 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateNovember 1, 2027
    Key ActionDocument the tumor type, rationale for unresectability when applicable, tumor size, and ablation modality.
    SourceLink
    POLICY UPDATE CHANGES

    Medically appropriate criteria were added for radiofrequency ablation of benign thyroid tumors.

    Medically appropriate criteria were added for cryoablation of osteoid osteoma.

    Medically appropriate criteria were added for desmoid tumors.

    Medically appropriate criteria were added for cryoablation and microwave ablation, and policy criteria were deleted in a positive coverage change.

    4 cmMaximum localized renal cell carcinoma lesion
    3 cmMaximum non-pulmonary lung metastasis size
    3 cmMinimum benign thyroid nodule size
    InvestigationalRFA for other solid tumors
    InvestigationalMWA outside liver, lung, kidney, or bone
    12%-15%HCC bridge-to-transplant dropout rate

    Medical Necessity and Coverage Criteria

    Hepatocellular Carcinoma — RFA

    Radiofrequency ablation (RFA) is considered medically appropriate for hepatocellular carcinoma when ANY of the following conditions is met:

    ANY of the following

    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions), and Milan criteria are met (e.g., a single tumor <= 5 cm or up to three lesions, each <= 3 cm).
    • The procedure is used as a bridge to transplant when the individual meets liver transplant criteria and is awaiting liver transplantation.

    Hepatic Metastases — RFA

    RFA is considered medically appropriate for the primary treatment of hepatic metastases when ALL of the following conditions are met:

    ALL of the following

    Policy Summary
    PayerUnivera Healthcare
    PolicyThermal Ablation for Solid Tumor Treatment
    Policy CodePolicy 7.01.111
    Change TypeModified
    Effective DateNovember 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateNovember 1, 2027
    Key ActionDocument the tumor type, rationale for unresectability when applicable, tumor size, and ablation modality.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Clinical ThresholdsDocumentation, Denial Risks, and Operational RulesPolicy BackgroundDefinitions and Technical ConceptsTreatment Line and Intent
    The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
  1. The metastases meet Milan criteria (e.g., a single tumor <= 5 cm or up to three lesions, each <= 3 cm).
  2. There is no evidence of uncontrolled extrahepatic systemic metastatic disease.
  3. Osteoid Osteoma — RFA

    Percutaneous RFA is considered a medically appropriate alternative to surgical excision when ALL of the following are met:

    ALL of the following

    • The treatment is for an osteoid osteoma.
    • The individual cannot be managed successfully with medical management.

    Painful Osteolytic Bone Metastases — RFA

    RFA is considered medically appropriate for palliation of pain when ALL of the following are met:

    ALL of the following

    • The individual has painful osteolytic bone metastases.
    • The individual has failed or is a poor candidate for standard treatments such as opioids or radiation.

    Localized Renal Cell Carcinoma — RFA

    RFA of localized renal cell carcinoma is considered medically appropriate when ALL of the following are met:

    ALL of the following

    • Lesion size is 4 cm or less in diameter.<= 4 cm
    • EITHER

      • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
      • ALL of the following

        • Treatment is necessary to preserve kidney function in an individual with significantly impaired renal status (i.e., the individual has one kidney or renal insufficiency defined by a glomerular filtration rate of <60 mL/min/m²).
        • Standard treatment is likely to substantially worsen kidney function.

    Non-Small Cell Lung Cancer — RFA

    RFA is considered medically appropriate to treat non-small cell lung cancer (NSCLC) when ALL of the following are met:

    ALL of the following

    • The lesion is isolated and peripheral and is 3 cm or less in size.<= 3 cm
    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions). Surgical resection or radiation treatment with curative intent is considered appropriate based on stage, but medical comorbidity renders the individual unfit for those interventions.

    Pulmonary Metastases from Non-Pulmonary Tumors — RFA

    RFA is considered medically appropriate to treat non-pulmonary tumors metastatic to the lung when ANY of the following pathways is met:

    ANY of the following

    • Surgical resection or radiotherapy is likely to substantially worsen pulmonary status and ablation is necessary to preserve lung function.
    • The individual is not a surgical candidate AND all of the following

      • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
      • Tumor size is 3 cm or less.<= 3 cm
      • There is no evidence of extrapulmonary metastases.
      • Twelve months have elapsed since the last ablation.>= 12 months

    Non-Pulmonary Tumors Metastatic to the Lung — RFA

    For non-pulmonary tumors metastatic to the lung, RFA is considered medically appropriate when the individual is not a surgical candidate and ALL treatment criteria are met:

    ALL of the following

    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
    • Tumor size is 3 cm or less.<= 3 cm
    • There is no evidence of extrapulmonary metastases.
    • Twelve months have elapsed since the last ablation.>= 12 months

    Symptomatic Uterine Fibroid Tumors — RFA

    Laparoscopic or transcervical ultrasound-guided RFA (e.g., the Acessa System or Sonata Device) is considered medically appropriate as an alternative to hysterectomy or myomectomy when ALL of the following are met:

    ALL of the following

    • The individual is 18 years or older.>= 18 years
    • ALL of the following

      • Symptoms are persistent and directly attributed to the uterine fibroid(s).
      • ANY of the following symptoms

        • Pelvic pain or pressure.
        • Gastrointestinal symptoms related to bowel compression (e.g., constipation or bloating).
        • Dyspareunia (pain during sexual relations).

    Benign Thyroid Nodules — Medical Appropriateness

    RFA is considered medically appropriate to treat benign thyroid nodules when ALL of the following are met:

    ALL of the following

    • The nodule is 3 cm or greater in diameter.>= 3 cm
    • The tumor is cytologically benign on fine-needle aspiration biopsy.
    • The individual is 18 years or older.>= 18 years
    • ANY of the following persistent symptoms directly attributed to benign thyroid tumor growth

      • Dysphagia, foreign-body sensation, or globus sensation.
      • Difficulty breathing or shortness of breath.
      • Neck discomfort, pain, pressure, tightness, or voice changes.
      • Chronic cough.

    RFA for Benign Thyroid Nodules — Complete Criteria

    RFA for benign thyroid nodules requires ALL decision criteria below:

    ALL of the following

    • The nodule is 3 cm or greater in diameter.>= 3 cm
    • The tumor is cytologically benign on fine-needle aspiration biopsy.
    • The individual is aged 18 years or older.>= 18 years
    • ANY of the following symptoms, persistent and directly attributed to benign thyroid tumor growth

      • Dysphagia, foreign-body or globus sensation.
      • Difficulty breathing or shortness of breath.
      • Neck discomfort, pain, pressure, tightness, or voice changes.
      • Chronic cough.

    RFA — Investigational Indications

    RFA is considered investigational for any other solid-tumor indication, including pancreatic and breast tumors.

    The proposed treatment is for a solid tumor other than an addressed covered indication, including pancreatic or breast tumors.

    Localized Renal Cell Carcinoma — CA

    Cryosurgical ablation (CA) of localized renal cell carcinoma is considered medically appropriate when ALL of the following are met:

    ALL of the following

    • Lesion size is 4 cm or less in diameter.<= 4 cm
    • EITHER

      • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
      • ALL of the following

        • Treatment is necessary to preserve kidney function in an individual with significantly impaired renal status (i.e., the individual has one kidney or renal insufficiency defined by a glomerular filtration rate of <60 mL/min/m²).
        • Standard treatment is likely to substantially worsen kidney function.

    Lung Cancer — CA

    CA may be considered medically appropriate for lung cancer when ANY of the following pathways is met:

    ANY of the following

    • The individual requires palliation for a central-airway-obstructing lesion.
    • Early-stage NSCLC pathway

      • The diagnosis is early-stage non-small cell lung cancer.
      • The individual is not receiving stereotactic radiotherapy or definitive radiation therapy.
      • The individual is considered high risk as a poor surgical candidate, consistent with applicable professional guidelines (including NCCN Guidelines for NSCLC).

    Desmoid Tumors — CA

    CA of desmoid tumors is considered medically appropriate as part of active therapy when ALL of the following are met:

    ALL of the following

    • The tumor is progressive, morbid, or symptomatic.
    • CA is being used as part of active therapy.

    Osteoid Osteoma — CA

    CA is considered medically appropriate as an alternative to surgical excision when ALL of the following are met:

    ALL of the following

    • The treatment is for an osteoid osteoma.
    • The individual cannot be managed successfully with medical management.

    Painful Osteolytic Bone Metastases — CA

    CA is considered medically appropriate for palliation of pain when ALL of the following are met:

    ALL of the following

    • The individual has painful osteolytic bone metastases.
    • The individual has failed or is a poor candidate for standard treatments such as opioids or radiation.

    CA — Investigational Indications

    CA is considered investigational for any tumor outside the addressed covered applications, including the following:

    The proposed treatment is for another tumor, including primary or metastatic liver malignancies, benign or malignant breast tumors, or pancreatic cancer.

    Hepatic Tumors — MWA

    MWA is considered medically appropriate for primary or metastatic hepatic tumors when ALL of the following are met:

    ALL of the following

    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
    • Milan criterion is met (e.g., a single tumor <= 5 cm or up to three nodules, each <= 3 cm).

    Hepatic Tumors — Complete MWA Criteria

    MWA is considered medically appropriate for primary or metastatic hepatic tumors when BOTH conditions are met:

    ALL of the following

    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
    • Milan criterion is met (e.g., a single tumor <= 5 cm or up to three nodules, each <= 3 cm).

    Pulmonary Tumors — MWA

    MWA is considered medically appropriate for primary or metastatic lung tumors when ALL of the following are met:

    ALL of the following

    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
    • The individual will not be receiving stereotactic radiotherapy or definitive radiation therapy.
    • Treatment is for a tumor that is 3 cm or less in size.<= 3 cm

    Renal Cell Carcinoma — MWA

    MWA is considered medically appropriate for renal cell carcinoma when ALL of the following are met:

    ALL of the following

    • The individual is not a surgical candidate (e.g., because of lesion location or comorbid conditions).
    • Biopsy of the lesion is recommended before or at the time of ablation.
    • Treatment is for a tumor that is 3 cm or less in size.<= 3 cm

    Osteolytic Bone Metastases — Palliative MWA

    MWA is considered medically appropriate for palliation of pain when ALL of the following are met:

    ALL of the following

    • The individual has osteolytic bone metastases with pain requiring palliation.
    • The individual has failed or is a poor candidate for standard treatments such as opioids or radiation.

    Osteoid Osteoma — Evidence and Coverage Criteria

    RFA for osteoid osteoma is supported by evidence showing outcomes comparable to surgical excision for tumor destruction and pain relief, with shorter hospital stays and quicker recovery. Coverage remains subject to the medical-necessity criteria below:

    ALL of the following

    • The treatment is for an osteoid osteoma.
    • The individual cannot be managed successfully with medical management.
    • The lesion is not large and is in a location that permits technically feasible percutaneous treatment.

    Bridge to Liver Transplant — RFA

    RFA may be used as a bridge to liver transplant for HCC when the individual meets transplant criteria and is awaiting transplantation.

    ALL of the following

    • The individual has hepatocellular carcinoma.
    • The individual meets liver transplant criteria, including applicable Milan criteria.
    • The individual is awaiting liver transplantation.

    Hepatic Metastases — Evidence-Supported Selected Populations

    Evidence supports RFA for selected hepatic metastatic populations when ALL of the following are met:

    ALL of the following

    • Selected metastatic population

      • Unresectable colorectal liver metastases without extrahepatic disease.
      • Neuroendocrine liver metastases in individuals whose symptoms are not controlled by systemic therapy or who are ineligible for resection.
    • The individual is not eligible for surgical resection or has unresectable disease.

    Renal Tumors — Selected cT1 Ablation Criteria

    Renal tumor ablation may be considered for selected cT1 renal tumors, with treatment selection based on tumor characteristics, biopsy information, surgical candidacy, and renal-preservation considerations.

    ALL of the following

    • The renal tumor is a selected clinical stage T1 tumor, particularly cT1a.
    • The individual is a poor candidate for surgery or renal preservation is of high priority.
    • The tumor is suitable for image-guided ablation and appropriate diagnostic evaluation, including biopsy when indicated.

    Insufficient Evidence — Indications Without Established Improved Net Health Outcomes

    The following indications are considered insufficiently supported because available evidence has not established improved net health outcomes compared with established treatment options:

    Insufficient-evidence indications

    • RFA for hepatic metastases that are neither colorectal nor neuroendocrine in origin.
    • Cryosurgical ablation for pancreatic cancer or other tumors outside addressed applications.
    • Other solid-tumor ablation indications lacking adequate comparative evidence.

    RFA coverage is not established for solid tumors outside the addressed medically appropriate applications, including pancreatic and breast tumors. Such indications are considered investigational.

    Cryosurgical ablation is considered investigational for tumors outside the addressed covered applications, including primary or metastatic liver malignancies, benign or malignant breast tumors, and pancreatic cancer.

    CA for tumors outside the addressed applications is investigational.

    MWA for primary or metastatic tumors other than liver, lung, kidney, or bone is considered investigational.

    Cryosurgical ablation for prostate cancer is not addressed in this policy.

    RFA for osteoid osteoma is not appropriate for large lesions or lesions in a location that makes percutaneous treatment technically difficult.

    Evidence is insufficient for using RFA specifically to downsize or downgrade HCC tumors to meet priority transplant criteria because outcomes have been inconsistent and longer-term follow-up is needed.

    For hepatic metastases that are neither colorectal nor neuroendocrine in origin, available evidence is limited by high-risk study designs and small sample sizes and is insufficient to establish improvement in net health outcomes.

    There is insufficient evidence that MWA improves health outcomes for solid-tumor indications other than hepatic and lung tumors; further comparative studies and longer follow-up are needed.

    Coding and Clinical Thresholds

    FDA Product Code — Cryosurgical Ablationmixed
    GEHFDA product code associated with cryosurgical ablation devices
    FDA Product Code — Microwave Ablationmixed
    NEYFDA product code associated with microwave ablation devices
    FDA device clearance identifiersmixed
    K121858FDA clearance identifier for the Acessa system for uterine fibroids
    CPT CodesCPT
    19105Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma.
    20982Ablation therapy for reduction or eradication of one or more bone tumors (e.g., metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; radiofrequency.
    20983Ablation therapy for reduction or eradication of 1 or more bone tumors (e.g., metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation.
    32994Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation.
    32998Ablation therapy for reduction or eradication of one or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, radiofrequency, unilateral.
    47370Laparoscopy, surgical, ablation of one or more liver tumor(s); radiofrequency.
    47371Laparoscopy, surgical ablation of one or more liver tumor(s); cryosurgical.
    47380Ablation, open, of one or more liver tumor(s); radiofrequency.
    47381Ablation, open, of one or more liver tumor(s); cryosurgical.
    47382Ablation, one or more liver tumor(s), percutaneous, radiofrequency.
    1–10 of 24
    1/3
    HCPCS CodesHCPCS
    C2618Probe/needle, cryoablation.
    C1886Catheter, extravascular tissue ablation, any modality (insertable).
    CPT CodesCPT
    60661Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)
    60699Unlisted procedure, endocrine system (*E/I when used for adrenal ablation [RF, CA, or MWA])
    76940Ultrasound guidance for, and monitoring of, parenchymal tissue ablation (*E/I when utilized for Microwave Ablation)
    77013Computed tomography guidance for, and monitoring of, parenchymal tissue ablation
    77022Magnetic resonance imaging guidance for, and monitoring of, parenchymal tissue ablation
    0581TAblation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral
    58580Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency (*E/I when utilized for CA or MWA)
    HCPCS CodesHCPCS
    C2618Probe/needle, cryoablation
    C1886Catheter, extravascular tissue ablation, any modality (insertable)
    ICD10 CodesICD-10
    Multiple CodesMultiple ICD-10 codes
    Milan criteria — single hepatic tumor
    ThresholdSingle hepatic tumor less than or equal to 5 cm
    CriterionMilan criteria
    ApplicationUsed in the cited eligibility criteria for hepatocellular carcinoma
    Milan criteria — multiple hepatic lesions
    Number of lesionsUp to three lesions
    Size limitEach lesion no greater than 3 cm in diameter
    CriterionMilan criteria
    Localized renal cell carcinoma lesion size
    Lesion size4 cm or less in diameter
    Tumor typeLocalized renal cell carcinoma
    TreatmentRadiofrequency ablation
    Renal insufficiency threshold
    ThresholdGlomerular filtration rate less than 60 mL/min/m²
    DefinitionRenal insufficiency
    Clinical contextSignificantly impaired renal status for kidney-preservation treatment
    Isolated peripheral NSCLC lesion size
    Lesion size3 cm or less
    Tumor typeIsolated peripheral non-small cell lung cancer
    TreatmentRadiofrequency ablation
    Tumor metastatic to the lung size
    Tumor size3 cm or less
    Tumor typeNon-pulmonary tumor metastatic to the lung
    Treatment pathwayRadiofrequency ablation for an individual who is not a surgical candidate
    Metastatic lung tumor size
    Maximum size3 cm or less
    DiseaseMetastatic lung tumor
    Eligibility contextNonsurgical-candidate pathway
    Metastatic lung tumor count
    Maximum numberNo more than three tumors per lung
    DiseaseNon-pulmonary tumors metastatic to the lung
    PurposeTumors to be ablated
    Interval since prior ablation
    Required intervalTwelve months have elapsed since the last ablation
    DiseaseNon-pulmonary tumors metastatic to the lung
    TreatmentRadiofrequency ablation
    Uterine fibroid size by device and approach
    Acessa laparoscopic RFAFibroids less than 10 cm in diameter
    Sonata transcervical RFAFibroids less than 7 cm in diameter
    Measurement methodUltrasound evidence
    Benign thyroid nodule size
    Minimum size3 cm diameter or greater
    Nodule typeBenign thyroid nodule
    TreatmentRadiofrequency ablation
    Localized renal cell carcinoma lesion size for cryoablation
    Lesion size4 cm or less in diameter
    Tumor typeLocalized renal cell carcinoma
    TreatmentCryosurgical ablation
    Renal insufficiency for kidney-preservation indication
    ThresholdGlomerular filtration rate less than 60 mL/min/m²
    IndicationKidney preservation
    TreatmentCryosurgical ablation for localized renal cell carcinoma
    Milan criteria — single HCC tumor
    Single tumor limit5 cm or less
    CriterionMilan criteria for hepatocellular carcinoma
    Clinical useLiver-transplant selection
    Milan criteria — three HCC tumors
    Number of tumorsThree tumors
    Size limitEach tumor 3 cm or less
    CriterionMilan criteria for hepatocellular carcinoma
    MWA ablation temperature
    TemperatureGreater than 100°C
    ModalityMicrowave ablation
    EffectHeating and coagulation of tissue adjacent to the probe
    MWA ablation area
    Ablation areaApproximately 2 cm to 3 cm
    ShapeElliptical area of tissue ablation
    ModalityMicrowave ablation
    HCC lesion burden evaluated in an RCT
    Lesion burdenUp to three lesions
    Size limitEach lesion 5 cm or smaller
    Study populationPatients with hepatocellular carcinoma in an RCT
    HCC clinical status evaluated in an RCT
    Liver functionChild-Pugh class A or B
    Metastatic statusNo extrahepatic metastases
    Invasion statusNo radiologic evidence of major vascular or bile duct invasion
    Liver tumor size associated with similar MWA and RFA outcomes
    Single-tumor populationSingle tumor 5 cm or less
    Multiple-tumor populationUp to three nodules, each 3 cm or less
    Outcome contextMWA and RFA had similar outcomes in the cited evidence
    Pulmonary tumors evaluated in cryoablation studies
    Maximum tumor size3.5 cm or less
    Tumor sitePulmonary tumors
    Study modalityCryoablation
    Pulmonary tumors evaluated in an MWA versus RFA RCT
    Single tumorUp to 5 cm
    Multiple metastasesUp to five metastases, each up to 5 cm
    Study comparisonMicrowave ablation versus radiofrequency ablation
    Juxtacardiac lung tumors evaluated with IGTA
    Distance from pericardium10 mm or less
    Tumor typeJuxtacardiac lung tumors
    TreatmentPercutaneous image-guided thermal ablation
    Renal tumors evaluated with percutaneous cryoablation
    Disease stageClinical stage T1 biopsy-proven renal cell carcinoma
    Lesion sizes11–58 mm
    TreatmentPercutaneous cryoablation

    Documentation, Denial Risks, and Operational Rules

    Documentation Required

    RFA for Metastatic Lung Tumors: Documentation Requirements

    For RFA of non-pulmonary tumors metastatic to the lung, document that the individual is not a surgical candidate and that all applicable criteria are satisfied.

    • Tumor size is 3 cm or less.
    • At least 12 months have elapsed since the last ablation.
    Documentation Required

    Uterine Fibroid RFA: Documentation Requirements

    For laparoscopic or transcervical ultrasound-guided RFA of uterine fibroids as an alternative to hysterectomy or myomectomy, document that all applicable criteria are met.

    • Individual is 18 years or older.
    • Ultrasound demonstrates fibroids are less than 10 cm for laparoscopic RFA with Acessa or less than 7 cm for transcervical RFA with Sonata.
    • Symptoms are persistent and directly attributable to the uterine fibroid(s).
    • Document at least one qualifying symptom: pelvic pain or pressure; gastrointestinal symptoms from bowel compression, such as constipation or bloating; or dyspareunia (pain during sexual relations).
    Documentation Required

    Benign Thyroid Nodule RFA: Documentation Requirements

    For RFA of benign thyroid nodules, document that all applicable criteria are met.

    • Nodule size is 3 cm in diameter or greater.
    • Individual is 18 years or older.
    Documentation Required

    Required Clinical Documentation

    Requests for thermal ablation should include the clinical documentation needed to establish the indication, medical necessity, and planned treatment.

    • Relevant history and physical demonstrating the tumor type.
    • Rationale explaining why the tumor is unresectable, when applicable.
    • Size of the tumor(s) to be treated.
    • Ablation modality to be utilized.
    Documentation Required

    Renal Lesion Biopsy Recommendation

    For MWA of renal cell carcinoma, a biopsy of the lesion is recommended before ablation or at the time of ablation.

    • Plan and document biopsy prior to or at the time of MWA.
    Denial Risk

    Denial Risk: Metastatic Lung Tumor RFA Criteria Not Met

    RFA for a non-pulmonary tumor metastatic to the lung may be denied when the individual is a surgical candidate or when the required clinical criteria are not documented or are not met.

    • Individual is not documented as not a surgical candidate.
    • Tumor is larger than 3 cm.
    • Fewer than 12 months have elapsed since the last ablation.
    Denial Risk

    Denial Risk: Uterine Fibroid RFA Criteria Not Met

    Uterine fibroid RFA may be denied when any required age, size, or symptom criterion is not met.

    • Individual is under 18 years.
    • Fibroids are 10 cm or greater for laparoscopic Acessa RFA or 7 cm or greater for transcervical Sonata RFA.
    • Symptoms are not persistent, are not directly attributable to the fibroids, or none of the qualifying symptoms is documented.
    Denial Risk

    Denial Risk: Benign Thyroid Nodule RFA Criteria Not Met

    RFA of a benign thyroid nodule may be denied when the nodule does not meet the required size or age criteria.

    • Nodule is less than 3 cm in diameter.
    • Individual is under 18 years.
    Denial Risk

    Investigational: RFA for Other Solid Tumors

    RFA is investigational for other solid tumors, including pancreatic and breast tumors.

    • Do not represent RFA for other solid tumors as medically appropriate under this policy.
    Denial Risk

    Investigational: Cryosurgical Ablation for Other Tumors

    Cryosurgical ablation is investigational for tumors outside the addressed applications, including primary or metastatic liver malignancies, breast tumors, and pancreatic cancer.

    • This includes benign and malignant breast tumors and pancreatic cancer.
    Denial Risk

    Investigational: Cryosurgical Ablation Outside Addressed Applications

    Cryosurgical ablation is investigational for other tumor indications not addressed as covered applications by the policy.

    • Do not assume FDA clearance of a device establishes coverage for an unaddressed tumor indication.
    Denial Risk

    Investigational: MWA Outside Specified Tumor Sites

    MWA for primary or metastatic tumors other than liver, lung, kidney, or bone is considered investigational.

    • Requests involving tumor sites outside liver, lung, kidney, or bone are investigational.
    Denial Risk

    Denial Risk: Pulmonary MWA Criteria Not Met

    MWA for a primary or metastatic lung tumor may be denied when any required condition is not met.

    • Individual is not documented as not a surgical candidate.
    • Individual will receive stereotactic radiotherapy or definitive radiation therapy.
    • Tumor is larger than 3 cm.
    Denial Risk

    Denial Risk: Renal MWA Criteria Not Met

    MWA for renal cell carcinoma may be denied when any required condition is not met.

    • Individual is not documented as not a surgical candidate.
    • Tumor is larger than 3 cm.
    • The recommended biopsy before or at the time of ablation is not planned or documented.
    Note

    Prostate Cancer Not Addressed

    Cryosurgical ablation for prostate cancer is not addressed in this policy.

    • Do not rely on this policy as a coverage basis for prostate cancer cryosurgical ablation.
    Denial Risk

    Technically Unsuitable Osteoid Osteoma

    RFA for osteoid osteoma is not appropriate for large lesions or lesions in locations that make percutaneous treatment technically difficult.

    • Assess and document lesion size and whether percutaneous access is technically feasible.
    • Avoid requesting RFA when the lesion is large or technically difficult to treat percutaneously.
    Denial Risk

    Insufficient Comparative Evidence: Breast Cancer Cryosurgery

    Available evidence for cryosurgery in breast cancer lacks control groups and comparative trials, so no conclusion can be made about net health outcomes.

    • Comparative trials are also lacking for fibroadenoma treatment.
    • Expect requests for breast cancer or fibroadenoma cryoablation to face insufficient comparative evidence.
    Denial Risk

    Insufficient Evidence: Transplant Downstaging

    Evidence is insufficient for using RFA specifically to downsize or downgrade tumors to meet priority liver-transplant criteria.

    • Inconsistent outcomes and the need for longer-term follow-up limit support for transplant downstaging.
    Denial Risk

    Insufficient Evidence: Non-CRC and Non-Neuroendocrine Hepatic Metastases

    For hepatic metastases that are neither colorectal nor neuroendocrine in origin, evidence for RFA is insufficient to establish improvement in net health outcomes.

    • Evidence is limited by high-risk study designs and small sample sizes.
    • Document that the metastases are not of colorectal or neuroendocrine origin when submitting such a request.
    Denial Risk

    Insufficient Evidence: Other Solid Tumors

    Evidence for RFA and MWA in other solid tumors is insufficient to establish improved health outcomes over established local or systemic treatments.

    • RFA evidence consists largely of case studies with short-term outcomes.
    • MWA evidence outside hepatic and lung tumors requires more rigorous comparative studies and longer follow-up.
    Denial Risk

    Insufficient Comparative Evidence: Pancreatic Cryosurgery

    Evidence for pancreatic cryosurgery consists primarily of retrospective, noncomparative case series and does not establish a net health benefit.

    • Reported pain relief is not supported by control-group comparisons.
    • Complications, including delayed gastric emptying, have been reported, but the true complication rate is uncertain.
    Denial Risk

    Investigational: Cryoablation in Unsupported Indications

    Cryoablation for unsupported indications is not supported by sufficient evidence to determine its effect on health outcomes.

    • Evidence is largely noncomparative case series with heterogeneous populations and limited long-term outcome data.
    • Comparative studies, larger samples, and longer follow-up are needed.

    Policy Background

    Thermal ablation provides a minimally invasive local-treatment option for selected solid tumors. Depending on the modality, treatment uses heat or freezing to destroy tumor tissue and may help preserve normal organ tissue, reduce morbidity, or shorten hospitalization when surgery or other standard local treatments are unsuitable. Coverage remains indication-specific and depends on the tumor site, disease extent, patient factors, and available evidence.

    Definitions and Technical Concepts

    Milan criteria definition
    Single-tumor criterionOne tumor measuring 5 cm or less
    Multiple-lesion criterionUp to three lesions, each no more than 3 cm in diameter
    UseIdentifies tumor burden for selected hepatic treatment and transplant criteria
    Renal insufficiency definition
    DefinitionGlomerular filtration rate below 60 mL/min/m²
    TermRenal insufficiency
    Clinical relevanceSignificantly impaired renal status
    Laparoscopic and transcervical ultrasound-guided RFA definition
    ProcedureUltrasound-guided radiofrequency ablation performed laparoscopically or transcervically
    Laparoscopic systemAcessa System
    Transcervical systemSonata Device
    Dyspareunia definition
    DefinitionPain during sexual relations
    Symptom typeSexual pain
    Clinical contextA qualifying symptom of symptomatic uterine fibroids
    Radiofrequency ablation definition
    TechniqueHeat-based thermal ablation
    Energy sourceHigh-frequency alternating current delivered through electrode tips
    Tissue effectFrictional heating and coagulative necrosis
    Microwave ablation definition
    TechniqueThermal ablation using microwave energy
    Tissue effectHeating and coagulation of tissue adjacent to the probe
    Typical ablation areaApproximately 2 cm to 3 cm elliptical area
    Cryosurgical ablation definition
    TechniqueThermal tumor ablation using subfreezing temperatures
    Delivery methodPenetrating or surface cryoprobes through which cryogen is circulated
    Cell-death mechanismsFreezing, protein denaturation, membrane rupture, dehydration, and ischemic hypoxia
    Milan criterion definition for hepatic tumors
    Single tumorNo greater than 5 cm
    Multiple nodulesUp to three nodules, each no greater than 3 cm in diameter
    CriterionMilan criterion
    Cryosurgical ablation technical definition
    TemperatureSubfreezing temperatures
    DeliveryPenetrating or surface cryoprobes containing circulating cryogen
    ResultCell death through freezing, protein denaturation, membrane rupture, dehydration, and ischemic hypoxia
    Microwave ablation technical definition
    Energy sourceMicrowave energy
    Tissue effectHeating and coagulation of tissue adjacent to the probe
    Ablation geometryTypically an elliptical area approximately 2 cm to 3 cm in size
    Radiofrequency ablation clinical definition
    TechniqueMinimally invasive thermal ablation
    Typical useInoperable tumors or patients ineligible for surgery
    Reasons for ineligibilityAdvanced age or comorbidities
    Milan criteria for HCC transplantation
    Single tumor5 cm or less
    Three-tumor limitThree tumors, each 3 cm or less
    Additional transplant criteriaNo macrovascular invasion and no metastasis
    Microwave ablation of liver tumors definition
    TechniqueAblation of liver tumors using electromagnetic microwave energy
    MechanismInduces thermal tissue destruction
    ModalityMicrowave ablation
    Cryoablation definition
    TechniqueLocal tumor-treatment technique using freezing
    PurposeDestroy tumor tissue
    ModalityCryoablation
    Image-guided thermal ablation definition
    TechniqueImage-guided thermal ablation performed percutaneously
    Included modalityCryoablation
    Included modalityMicrowave ablation

    Treatment Line and Intent

    First-line treatment designation

    Desmoid-tumor cryoablation may be used as a local therapy option in the first-line setting when:

    First-line treatment setting: Cryoablation is used as local therapy for an inoperable, symptomatic, or progressive desmoid tumor, particularly when systemic therapy is not preferred.

    Published cohorts included first-line use; this is descriptive treatment-setting evidence rather than an additional authorization requirement.

    Salvage treatment designation

    Desmoid-tumor cryoablation may be used in the salvage setting when:

    Salvage treatment setting: The symptomatic or progressive desmoid tumor has progressed after prior medical therapy and the individual is not a candidate for surgery.

    This reflects CRYODESMO-01 study eligibility and is descriptive treatment-setting evidence rather than an additional authorization requirement.